Zivo Bioscience (Zivo Bioscience) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience Change In Receivables?

Zivo Bioscience's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Zivo Bioscience's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Zivo Bioscience's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.00 Mil. It means Zivo Bioscience's Accounts Receivable increased by $0.00 Mil from Dec. 2022 to Dec. 2023 .

Zivo Bioscience's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zivo Bioscience's Days Sales Outstanding for the three months ended in Mar. 2024 was 10.14.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zivo Bioscience's liquidation value for the three months ended in Mar. 2024 was $-2.94 Mil.

Zivo Bioscience Change In Receivables Historical Data

The historical data trend for Zivo Bioscience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zivo Bioscience Change In Receivables Chart

Zivo Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Zivo Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Zivo Bioscience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Zivo Bioscience (OTCPK:ZIVO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zivo Bioscience's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.004	/	0.036	*	91
=	10.14

2. In Ben Graham's calculation of liquidation value, Zivo Bioscience's accounts receivable are only considered to be worth 75% of book value:

Zivo Bioscience's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.139	-	3.085	+	0.75 * 0.004	+	0.5 * 0
=	-2.94

Zivo Bioscience Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zivo Bioscience (Zivo Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304

Website

https://www.zivobioscience.com

Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's pipeline candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Human Food Ingredients, and Skin Health.

Executives

Alison A Cornell	director	210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore	officer: CHIEF FINANCIAL OFFICER	4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson	director	768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
John Bernard Payne	director	9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Strome Mezzanine Fund, Lp	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando	officer: Chief Financial Officer	C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome	10 percent owner	100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P	10 percent owner	100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp	10 percent owner	100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc.	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc	10 percent owner	2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr	director	70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox	director	470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl	officer: President, CEO	7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young	other: See remarks below.	1800 NW CORPORATE BLVD, BOCA RATON FL 33431